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BACKGROUND: It is widely recognised that sorafenib inhibits a range of molecular targets in renal cell carcinoma (RCC). In this study, we
aim to use patient-derived RCC xenografts to delineate the angiogenic and non-angiogenic molecular targets of sorafenib therapy for
advanced RCC (aRCC).
METHODS: We successfully generated three patient RCC-derived xenografts in severe combined immunodeficient mice, consisting of
three different RCC histological subtypes: conventional clear cell, poorly differentiated clear cell RCC with sarcomatoid changes, and
papillary RCC. This study also used clear cell RCC cells (786-0/EV) harbouring mutant VHL to investigate the clonogenic survival of
cells transfected with survivin sense and antisense oligonucleotides.
RESULTS: All three xenografts retain their original histological characteristics. We reported that sorafenib inhibited all three RCC
xenograft lines regardless of histological subtypes in a dose-dependant manner. Sorafenib-induced growth suppression was associated
with not only inhibition of angiogenic targets p-PDGFR-b, p-VEGFR-2, and their downstream signalling pathways p-Akt and p-ERK,
cell cycle, and anti-apoptotic proteins that include cyclin D1, cyclin B1, and survivin but also upregulation of proapoptotic Bim. Survivin
knockdown by survivin-specific antisense-oligonucleotides inhibited colony formation and induced cell death in clear cell RCC cells.
CONCLUSION: This study has shed light on the molecular mechanisms of sorafenib in RCC. Inhibition of non-angiogenic molecules by
sorafenib could contribute in part to its anti-tumour activities observed in vivo, in addition to its anti-angiogenic effects.
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Renal cell carcinoma (RCC) is the most lethal of all urological
cancers. Approximately 20–30% of patients with RCC exhibit
visceral metastasis at the time of diagnosis (Griffin et al, 2007) and
of all patients with clinical organ-confined disease, who had
undergone potentially curative radical nephrectomy, 30% will
develop metastatic disease on follow-up (Zisman et al, 2002). Until
recently, the only effective treatment for metastatic RCC was
cytokine-based immunotherapy with interferon-a or interleukin-2,
which produce a response rate of only 10–15%. The advent of
molecular targeted therapy in the last few years has revolutionised
treatment of patients with metastatic RCC with benefits in terms of
disease stabilisation, improvement of quality of life, and, in the
case of sunitinib, overall survival (Atkins et al, 2004; Escudier et al,
2007; Heng et al, 2009; Motzer et al, 2009).
Sorafenib is a small molecule tyrosine kinase inhibitor (TKI)
currently FDA approved for advanced RCC (aRCC). It is however
not tyrosine kinase receptor (TKR) specific. Indeed, sorafenib
(BAY 43-9006) was initially developed as a Raf inhibitor in the
class of bis-aryl ureas that inhibits several RTKs, including
VEGFR-2 and -3, PDGFR-b, FLT3 receptor, and c-KIT receptor
(Wilhelm et al, 2004; Fabian et al, 2005). Although many trials
reported clinical efficacies of this new therapeutic, the exact
molecular mechanism(s) accounting for its clinical effects is still
largely unknown. In addition, there are currently no reliable
molecular biomarkers available to predict for treatment responses
to this new class of therapeutics. A tumour xenograft model
provides a means for pre-treatment drug testing, which allows the
study of molecular changes in tumour in response to treatment,
which hopefully will lead to better understanding of the molecular
mechanisms underlying the clinical activity of sorafenib in RCC.
In this study, we developed RCC-derived xenografts in severe
combined immunodeficient (SCID) mice and use them to assess
tumour response to sorafenib, and to assess whether treatment
responses is RCC subtype dependant. Second, we aim to gain
insight into sorafenib-induced molecular changes in the TKR
expression profile and the associated downstream signalling
pathways.
MATERIALS AND METHODS
Drugs and reagents
Research-grade Capsitol was purchased from CyDex, Inc., Lenexa,
KS, USA. Primary antibodies against CD31 and Ki-67 were
from Lab Vision, Fremont, CA, USA. Anti-cleaved caspase-3,
anti-cleaved PARP, Akt, Bim, PDGFR-b, and phosphorylation-
specific antibodies against eIF4E Ser209, ERK1/2 Thr202/Tyr204,
and Akt Ser473 were obtained from Cell Signalling Technology
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s(Beverly, MA, USA). Antibodies against cyclin D1, cyclin B1,
cyclin A, cdk-2, cdk-4, cdk-6, p27, Bax, Bad, Bcl-xL, Mcl-1,
survivin, ERK1/2, VEGFR-2, phospho-VEGFR-2 Tyr951, phospho-
PDGFR-b Tyr1021, and a-tubulin were from Santa Cruz Biotech-
nology Inc. (Santa Cruz, CA, USA). Sorafenib tosylate (BAY 43-
9006, Nexavar, Bayer and Onyx Pharmaceuticals) was purchased
from Bayer HealthCare (Leverkusen, Germany). Sorafenib was
dissolved in vehicle (30% Capsitol in water) before use.
Creation of human RCC-derived xenografts in SCID mouse
Prospectively over 1 year (July 2008–July 2009), patients under-
going nephrectomy for RCC were recruited in the study with
informed consent and with approval from our Institution Review
Board. In addition, approval was granted by our Institutional
Animal Care and Use Committee for in vivo experiments involving
animals. The conduct of all experiments involving mice adhered
strictly to the standard as outlined in the guidelines for the welfare
and use of animals in cancer research by Workman et al (2010).
Specimens from nephrectomy performed for RCC were obtained
intraoperatively. The diagnoses of RCC were confirmed by
histology in all cases. Renal cell carcinoma xenografting was
carried out with mice (Animal Resource Centre) that are
homozygous for the SCID mutation as previously described
(Huynh et al, 2006). Briefly, freshly sectioned RCC tissues were
placed in RPMI 1640 in an ice bath immediately on tumour
sectioning. Thin slices of tumour, taken between contiguous thin
slices used for cryostat section and permanent sections (paraffin-
embedded sections), were weighed, diced into 2–3mm
3 pieces,
and washed three times with RPMI 1640 medium. They were
minced finely to fragments that passed through an 18-gauge
needle. They were then mixed 1:1 (V/V) with Matrigel (Colla-
borative Research, Bedford, MA, USA) to give a total volume of
0.2ml per injection. The tissue mixture was subcutaneously
injected in the right flank of 8-week-old male SCID mice. For
each tumour, five mice were used. Growth of established tumour
xenografts was monitored at least twice weekly for 5 months. For
serial transplantation, tumour-bearing animals were killed by CO2
exposure. Animals were placed in ice water bath for 2min. They
were then dipped in and out of 10% Clorox (The Clorox Company,
Oakland, CA, USA) solution for 2min, washed in four changes of
ice water, placed in 70% ethanol, and transferred to a laminar flow
hood for dissection. Tumours were minced under sterile condi-
tions as described above. Fragments that passed through an 18-
gauge needle were mixed with Matrigel for serial transplantation in
successive SCID mice.
Testing the efficacy of sorafenib on RCC xenografts
Drug testings were carried out to assess the efficacy of sorafenib in
RCC. In brief, mice bearing indicated xenografts (10 per group)
were orally administered 200ml of vehicle (30% Capsitol), or
40mgkg
 1 per day sorafenib. Growth of established xenografts
was monitored at least twice weekly by Vernier caliper measure-
ment of the length (a) and width (b) of the tumour. Tumour
volume was calculated as (a b
2)/2. Animals were killed at a pre-
determined duration after the last treatment dose, and body and
tumour weights were recorded, with tumours collected for further
molecular analyses. To study the effects of therapeutic agents on
apoptosis cascade activation and TKR signalling pathway activa-
tion, mice bearing RCC tumours were treated with vehicle or drugs
per kilogram of body weight as described above. Animals were killed
at 3h after the last dose, and tumours were collected and frozen in
liquid nitrogen for later analysis to correlate drug responses with
tumour biology. Part of the tumour collection was fixed in neutral
buffer containing 10% formalin for immunohistochemistry.
For dose–response experiments, 12 clear cell RCC (RCC-07-
0408) tumour-bearing SCID mice were randomly divided equally
into four groups. Mice bearing tumours were orally treated with
200ml of vehicle (30% Captisol) or two doses of sorafenib (20 and
40mgkg
 1) daily for 21 days, when tumours were approximately
150–180mm
3. Tumour growth was determined as described
above. Animals were killed on day 21 of treatment and their
tumour weight was recorded.
Antisense survivin treatment
Antisense survivin oligonucleotide (ASO) (kindly provided by
Eli-Lilly, Indianapolis, IN, USA) is the sodium salt of a
synthetically derived 18-mer phosphorothioate oligonucleotide
composed of eight methoxyethyl-modified ribonucleotides and
10 deoxy-ribonucleotides (LY2181308). The sequence of nucleo-
tides is complementary to mRNA involved in the biosynthesis of
survivin. LY2181308 hybridises in an antisense orientation to the
survivin mRNA (Accession # NM_001168) at position 1099–1116.
mismatch control oligonucleotide (MM control LY2293329) for the
LY2181308 sodium was prepared by incorporating six mismatch
bases while maintaining the same G/C content as that of the
antisense molecule.
For gene silencing experiments by survivin ASO, 786-0 cells
were transfected with LY2181308 sodium or control LY2293329
using LipofectAmine 2000 in Opti-MEM medium (Invitrogen,
Carlsbad, CA, USA). Samples were collected after 72h and
analysed by immunoblotting or flow cytometry analysis.
Western immunoblot analysis
To determine changes in indicated proteins, eight independent
tumours from vehicle- or drug-treated mice were homogenised.
Lysates of four tumours from one group were pooled. Each lane
represented one protein pool (80mg of proteins) and two pools per
group were subjected to western blotting as described (Huynh
et al, 2006).
Immunohistochemistry
Tumour tissue samples were processed for paraffin embedding and
5mm sections were prepared. The sections were incubated overnight
at 41C with the primary antibodies against CD31, Ki-67, and cleaved
PARP as described previously (Huynh et al,2 0 0 8 ) .
Clonogenic survival assay
Clonogenic assays were performed as described (Rochester et al,
2005). In brief, at 48h after survivin-specific ASO transfection,
cells were re-seeded in 10cm dishes at 1500 cells per dish. The
remaining cells were pelleted by centrifugation at 13000r.p.m. at
41C, washed with ice-cold PBS, and lysed for immunoblotting to
quantify survivin gene silencing. Clonogenic assay dishes were
incubated at 371Ci n5 %C O 2 for 10–14 days until discreet colonies
were visible. Visible colonies were fixed in methanol/acetic acid
(3:1), stained with crystal violet (400mgml
 1; Sigma, St Louis,
MO, USA), and counted on an automated colony counter
(ColCount, Oxford Optronix, Oxford, UK).
Statistical analysis
The graphing and statistical analysis software Prism v.4.0
(GraphPad, La Jolla, CA, USA) and Excel (Microsoft, San Diego,
CA, USA) were used to plot and analyse data. Graphs were plotted
to show mean values and error bars. Error bars depict standard
error of the mean (s.e.m.). The Student’s t-test and analysis of
variance with Bonferroni post hoc test were used for the
comparison of mean values between two and multiple (42) data
sets, respectively. For the in vivo experiments, changes in body
weight and tumour weight at killing, mean vessel density, Ki-67
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sindex, and apoptotic cells were compared using Student’s t-test. A
minimum of 95% level of significance (i.e., a P-value of less than
0.05) was used to define statistical significance.
RESULTS
Three RCC xenografts derived from nephrectomised RCC speci-
mens were established. Supplementary Figure 1S shows the
histological phenotype of xenografts RCC-07-0408, RCC-02-0908,
and RCC-25-0908, which were conventional clear cell, papillary,
and poorly differentiated clear cell RCC with sarcomatoid changes,
respectively. In comparison with the histological features of the
clinical specimens, the three established xenografts retain identical
histological characteristics compared with the original tumour.
We next proceeded to evaluate the ability of sorafenib to suppress
the growth of patient-derived RCC xenograft RCC-07-0408,
which is of clear cell histological subtype. As illustrated
in Figure 1, the growth rate of RCC-07-0408 was inhibited by
sorafenib in a dose-dependent manner (Figure 1A). Tumour
weights of mice treated with 20 and 40mgkg
 1 sorafenib for
21 days were B26 and 15% of that treated with vehicle,
respectively, (Figures 1B and C, Po0.01). Similarly, treatment of
RCC-02-0908 (papillary RCC) and RCC-25-0908 (poorly differ-
entiated clear cell sarcomatoid RCC) xenografts with 40mgkg
 1
sorafenib also resulted in significant growth inhibition (Figure 2,
Po0.01). At a dose of 40mgkg
 1, sorafenib did not elicit any overt
toxicity, as manifested by weight loss, unkempt appearance,
mortality, and distress behaviour, in all sorafenib-treated animals
during the course of treatment.
We next examined the anti-angiogenic, anti-proliferative, and
apoptotic effects of sorafenib in treated tumour xenografts.
Representative CD31, Ki-67, cleaved PARP, VEGF, and p-ERK1/2
immunohistochemical stainings for vehicle- and sorafenib-treated
RCC-07-0408 and RCC-02-0908 tumour xenografts were shown in
Figure 3. Sorafenib-treated xenografts demonstrated significant
decrease in mean percentage of CD31-positive endothelial cells in
both xenografts compared with vehicle-treated xenografts
(Po0.05). In relation to this, there was no difference in the
expression of VEGF between the sorafenib- and vehicle-treated
xenografts, however, the former demonstrated significant decrease
in p-ERK staining compared with the latter (Po0.05). This finding
is consistent with inhibition by sorafenib of the angiogenic
pathway mediated by VEGFR and PDGFR in endothelial cells. In
addition, there was a significant increase in apoptosis (percentage
of cleaved PARP-positive cells) and a significant decrease
in proliferation (percentage of Ki-67-positive cells) (Po0.05)
observed in both sorafenib-treated xenografts compared with
the vehicle-treated control. Similar results were obtained when
RCC-25-0908 tumours were analysed (Supplementary Figure 2S).
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Figure 1 Effects of sorafenib on the growth of RCC-07-0408 xenograft.
Mice bearing RCC-07-0408 tumours were randomised (10 mice per
group) and treated with vehicle or two doses of sorafenib (20mg and
40mgkg
 1 per day) for 21 days. Mean of tumour volume±s.e. at given
time points (A), representative vehicle- and sorafenib-treated tumours (B),
and the corresponding tumour weight (C) for RCC-07-0408 xenograft are
shown. The asterisks (* and **) indicated significant differences between
the vehicle- and sorafenib-treated tumours (Po0.05 and Po0.001
respectively, analysis of variance). Experiments were repeated twice with
similar results.
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Figure 2 Effects of sorafenib on the growth of RCC-02-0908 and RCC-
25-0908 xenografts. Mice bearing indicated tumours were randomised
(10 mice per group) and treated with vehicle or 40mgkg
 1 sorafenib for
21 days. Representative vehicle- and sorafenib-treated tumours (A), and
the corresponding tumour weight (B) for indicated xenografts are shown.
The asterisks (*) indicated significant differences between the vehicle- and
sorafenib-treated tumours (Po0.05, analysis of variance). Experiments
were repeated twice with similar results.
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we determined whether sorafenib could effectively inhibit its
targeted receptors: VEGFR-2 (Flk1), and PDGFR-b. As shown in
Figure 4A and Supplementary Figure 3S, sorafenib was clearly
effective in inhibiting the phosphorylation of VEGFR-2 Tyr951 and
PDGFR-b Tyr1021. As sorafenib has been shown to target the
Raf/MEK/ERK pathway (Wilhelm et al, 2004; Liu et al, 2006), we
proceeded to examine whether sorafenib-induced tumour growth
suppression in RCC-derived xenografts was associated with
inactivation of this signalling pathway. Figure 4 shows that
although p-c-Raf Ser338 levels were not significantly altered, the
levels of p-ERK1/2 and p-AKT Ser473 in sorafenib-treated tumours
were lower than those observed in vehicle-treated tumours. These
findings are in contrast to our previous observation that sorafenib
induces paradoxical ERK signalling pathway in gastric carcinoma
through upregulation of p-c-Raf Ser338 (Yang et al, 2009).
The exact mechanistic explanation for this phenomenon in gastric
carcinoma is unclear at the moment. However, our finding
showing sorafenib-induced inhibition of both PI3K/AKT and
MAPK/ERK pathways in RCC is consistent with sorafenib as a TKI.
As cell cycle proteins might have a significant role in the
development of RCC, we evaluated the effect of sorafenib in
regulating cell cycle proteins (Figure 4B and Supplementary
Figure 3S). Our data showed that although expression of cdk-4,
cdk-6, and p27 was not affected by sorafenib, the levels of cyclin D1,
cyclin cdk-2, and cyclin B1 in sorafenib-treated tumours were
significantly reduced as compared with controls (Po0.05). These
findings suggest that inhibition of cell cycle progression in vivo may
prove to be one of the mechanisms accounting for the clinical
effects of sorafenib in RCC. We next proceeded to investigate
the effect of sorafenib on apoptosis induction. Figure 4C and
Supplementary Figure 3S demonstrated that sorafenib also induced
profound apoptosis as evidenced by the generation of PARP cleavage
products. Although the proapoptotic protein Bim was significantly
increased in sorafenib-treated xenograft, expression of the anti-
apoptotic protein Mcl-1 was reduced (Figure 4C; Po0.05). There are
no significant alterations in the levels of Bax, Bad, p-c-myc Thr58/
Ser62, p-eIFG4E Ser209, and Bcl-xL following sorafenib treatment.
In addition, we found significant downregulation of survivin in
tumours treated with sorafenib compared with controls (Figure 4C
and Supplementary Figure 3S). The magnitude of change of survivin
parallels tumour growth inhibition.
To examine the role of survivin in RCC cell proliferation and
survival we knocked down survivin expression in 786-0 RCC cells
using LY2181308 sodium, a specific antisense survivin oligonu-
cleotide. As shown in Figure 5A, transfection of 786-0 cells with
LY2181308 sodium resulted in significant reduction in survivin
levels as determined by western immunoblotting. Transfection of
786-0 cells with the LY2181308 sodium also resulted in an increase
in multinucleated cells (Figure 5A, lower panel). Morphologically,
these cells became abnormally large, flattened, and accumulated
nuclei. The levels of p21 and cleaved PARP were also elevated.
Next, experiments were conducted to assess the effects of survivin
knockdown on clonogenic survival measured under anchorage-
dependent conditions (Figure 5B). We demonstrated that survivin
depletion by ASO induced significant inhibition of clonogenic
survival, to B5% of control transfected cultures in 786-0 cells
(Po0.001). The results suggest that survivin is a critical factor for
the proliferation, cytokinesis, and survival of RCC cells.
DISCUSSION
The introduction of molecular targeted therapy has revolutionised
treatment of patients with aRCC. However, there has been a lack
of data delineating the exact molecular mechanisms accounting
for the clinical effects of such therapy in aRCC. In this study, we
developed a patient-derived RCC xenograft model to study
molecular changes in RCC xenografts in response to treatment
by sorafenib. We report the establishment of three patient-derived
xenografts from RCC tumours and have shown that these
xenografts exhibit cellular and tissue characteristics that are
very similar to the original tumours. These tumours include
a conventional clear cell RCC, a papillary RCC, and a poorly
differentiated clear cell RCC with sarcomatoid changes.
A sarcomatoid component can occur in all RCC histological
subtypes and signifies an aggressive disease with poor prognosis.
Our study shows that the clinical activities of sorafenib are
mediated not only through VEGFR and PDGFR, and their principal
downstream signalling pathways (Raf/MEK/ERK and PI3K/AKT)
but also through inhibition of non-angiogenic pathways that
include inhibition of apoptosis, cell cycle proteins, and survivin,
which are not previously reported.
RCC-07-0408
CD31
Ki-67
Cleaved PARP
VEGF
p-ERK
Vehicle Sorafenib
Figure 3 Effects of sorafenib on phospho-ERK1/2, VEGF expression,
angiogenesis, cell proliferation and apoptosis of RCC-07-0408 xenograft.
Mice bearing RCC-07-0408 tumours were randomised (10 mice per
group) and treated with vehicle or 40mgkg
 1 per day sorafenib for
21 days. Representative pictures of blood vessels stained with anti-CD31,
proliferative cells stained with anti-Ki-67, apoptotic cells stained with
anti-cleaved-PARP, VEGF expression stained with anti-VEGF, and p-ERK1/2
stained with anti-phospho-ERK antibodies in vehicle- and drug-treated
tumours are shown ( 200). Experiments were repeated twice with similar
results.
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sIn this study, we showed that inhibitions of phosphorylation of
VEGFR-2 and PDGFR-b were detected in the sorafenib-treated
tumours (Figure 4A). It is known that VEGF promotes prolifera-
tion, migration, invasion, and survival of endothelial cells (Tran
et al, 1999) and the migratory process is in part mediated by
activation of Raf/MEK/ERK signalling cascades (Graf et al, 1997;
Pukac et al, 1998). It is possible that the potent anti-angiogenic
effects of sorafenib in RCC xenograft may therefore be a result of
direct functional impairment of tumour-vessel-associated endo-
thelial cells and vascular smooth muscle cells. By disrupting VEGF
signalling, sorafenib is able to inhibit VEGF-driven tubular
formation, and endothelial cell migration and sprouting, leading
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Figure 4 Effects of sorafenib therapy on the phosphorylation of VEGFR-2, FGFR-1, PDGFR-b, ERK pathway, Akt, (A) expression of cell cycle regulatory
proteins (B), and apoptosis (C) in RCC-07-0408 xenografts. Mice bearing RCC-07-0408 tumours were randomised (10 mice per group) and treated with
vehicle or two doses of sorafenib (20mg and 40mgkg
 1 per day) for 21 days. Lysates of four tumours from one group were pooled. Each lane represented
one protein pool and two pools per group were subjected to western immunoblot analysis as described under the Materials and Methods section.
Representative blots are shown. Experiments were repeated twice with similar results.
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Figure 5 Effects of survivin knockdown on anchorage-dependency, cytokinesis, expression of cell cycle regulatory proteins, and apoptosis in 786-0 cells.
786-0 cells were transfected with sense and antisense survivin as described under the Materials and methods section. At 48h after transfection, cells were
collected, extracted, and cell lysates were subjected to western immunoblot analysis as described under Materials and methods (A). Representative
morphology of survivin-sense and antisense-transfected cells is shown in (B). For clonogenic assay, cells were seeded in triplicate at a density of 1500 cells
per 10cm dish and allowed to grow for 7–10 days until visible colonies were formed. The results are presented as percentage of the number of colonies
formed relative to control (sense survivin treated) dishes (n¼3). Bars represent mean±s.e.m. Representative dishes of control (survivin sense) and survivin
antisense transfected cells are shown in the lower panel. Survivin depletion induced significant inhibition of clonogenic survival, to o90% of control
transfected cultures (Po0.001).
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sto a striking reduction in tumour growth and microvessel density
as observed in sorafenib-treated RCC xenografts (Figure 3). The
PDGF is angiogenic for microvascular sprouting of endothelial
cells, in particular PDGF-BB and receptors recruit pericytes and
smooth muscle cells around nascent vessel sprouts (Conway et al,
2001). This pericyte–endothelial interaction normally confers
resistance to VEGFR antagonists on endothelial cells (Erber et al,
2004). Thus, the inhibition of both PDGFR and VEGFR by
sorafenib may enhance tumour vessel regression by disruption
of the pericyte-mediated endothelial cell survival mechanisms, as
shown in Figure 3.
Our findings showed that sorafenib induces comparable tumour
inhibition in conventional clear cell (RCC-07-0408), papillary
(RCC-02-0908), and poorly differentiated clear cell sarcomatoid
(RCC-25-0908) RCCs, suggesting that the clinical effect of
sorafenib in RCC is not limited to conventional clear cell RCC
subtype. This suggests that inhibition of angiogenic targets
(VEGFR and PDGFR) may not be the only mechanism of action
that contributes to the clinical effects of sorafenib. Inhibition
of non-clear cell RCC by sorafenib could be mediated by inhibition
of non-angiogenic pathway, including its effects on cell cycle,
apoptosis, and survivin expression.
As for the effects of sorafenib on cell cycle in RCC, we showed
that sorafenib-induced growth suppression was associated with
inhibition of cyclin D1, cyclin B1, and apoptosis induction. As
cyclin D1 is required for G1 cell cycle progression, inhibition of
cyclin D1 expression by sorafenib would arrest the cells at G1/S
phase. Also our present study shows that sorafenib actively
induces apoptosis. However, the mechanism(s) responsible for this
effect is not clear at the moment. Bim (also known as BCL2-like 11)
is a proapoptotic member of the Bcl-2 family implicated in the
regulation of apoptosis associated with thymocyte negative
selection and following growth factor withdrawal (Whitfield
et al, 2001; Bouillet et al, 2002; Ley et al, 2003). It is possible
that upregulation of Bim by sorafenib would allow more Bim to
bind to and antagonise anti-apoptotic effect of the Bcl-2 and
Bcl-xL, leading to Bax-dependent apoptogen release, caspase
activation, and cell death.
Lastly, we showed that in addition to inhibition of angiogenic
pathways, sorafenib also suppressed survivin expression. Survivin
knockdown by survivin-specific ASO inhibited cell growth and
induced cell death in clear cell RCC cells. We hypothesised that
inhibition of survivin may contribute to the clinical activities of
sorafenib, an observation substantiated by the fact that the degree
of survivin suppression correlates well with the degree of tumour
growth suppression by these drugs. The findings have important
clinical implications as this observation renders survivin a target
for therapeutic development of aRCC. The mechanistic pathway
leading to suppression of survivin by sorafenib is unclear at the
moment. It is postulated that the downregulation of survivin was a
result of VEGFR/PDGFR inhibition by sorafenib as survivin
expression is regulated by TKR activity (Sato et al, 2006).
However, the exact mechanism of survivin suppression by
sorafenib, which could be a direct effect or mediated through
other signalling pathways, is currently being investigated.
A study using a murine xenograft model however has its
inherent limitations. First, the uptake rate of xenograft in SCID
mice in our experience is about 30–40%. Clinical conclusions
based on data derived from a limited number of RCC xenografts
should be interpreted with caution. Second, even though we
demonstrated that the xenografts we generated retain identical
histological features compared with the original specimens,
tumour behaviour in a non-orthotropic environment in mice
may not resemble the microenvironment of RCC in patients. Thus,
it is possible that tumour response in a xenograft model may not
be reproducible clinically. Nevertheless, our molecular data
generated using RCC-derived xenografts is consistent and
reproducible, and it sheds light into the molecular mechanisms
accounting for the clinical effects of sorafenib in aRCC.
In summary, we have shown that both clear cell and non-clear
cell RCCs responded to treatment with sorafenib. In addition, we
have presented novel findings on the effects of sorafenib on non-
angiogenic targets that include proteins involve in cell cycle
regulation, apoptosis, and survivin, which may contribute to the
overall clinical activity of sorafenib in RCC, in addition to
inhibition of both the AKT and ERK signalling pathways down-
stream of VEGFR and PDGFR. These non-angiogenic targets could
explain the observation that clinical activity of sorafenib in RCC is
not limited to the conventional clear cell histological subtype.
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